In the secondary analysis, the fewer conservative but clinically meaningful criterion of steady reaction (outlined for a 50% or more reduction in MADRS from baseline for 2 weeks) was used. Of your patients who reached steady reaction, 25.eight% while in the esketamine group and 57.6% during the placebo group relapsed, https://aaronz589wsn7.blogsidea.com/profile